论文部分内容阅读
冠心病是21世纪严重危害人类健康的常见病,经皮腔内冠状动脉介入治疗(PCI)是目前冠心病血运重建的主要方法,尽管随着雷帕霉素、紫杉醇、西莫罗斯等药物涂层支架的临床应用,有效降低了支架内再狭窄的发生率。然而药物涂层支架(DES)亦存在支架内血栓形成的风险,抗PCI术后支架内再狭窄药物的研究开发依然是目前PCI研究中的核心问题。昆明山海棠(THH)具有抗炎、抗免疫、抑制平滑肌细胞增殖和抑制损伤血管新生内膜形成等作用,在PCI术后再狭窄中具有一定的应用前景。
Coronary heart disease is a common disease that seriously endangers human health in the 21st century. Percutaneous transluminal coronary intervention (PCI) is the main method of revascularization in coronary heart disease. Although with the increasing of rapamycin, paclitaxel, The clinical application of coated stents effectively reduces the incidence of in-stent restenosis. However, drug-eluting stents (DES) also present a risk of stent thrombosis. The development of anti-stenosis in-stent restenosis after anti-PCI remains a central issue in PCI studies. Kunming Begonia (THH) has anti-inflammatory and anti-immune effects, inhibits the proliferation of smooth muscle cells and inhibits the neovascularization of injured neovascularization. It has certain application prospects in restenosis after PCI.